258 related articles for article (PubMed ID: 16143300)
1. Lanthionine introduction into nukacin ISK-1 prepeptide by co-expression with modification enzyme NukM in Escherichia coli.
Nagao J; Harada Y; Shioya K; Aso Y; Zendo T; Nakayama J; Sonomoto K
Biochem Biophys Res Commun; 2005 Oct; 336(2):507-13. PubMed ID: 16143300
[TBL] [Abstract][Full Text] [Related]
2. Engineering unusual amino acids into peptides using lantibiotic synthetase.
Nagao J; Shioya K; Harada Y; Okuda K; Zendo T; Nakayama J; Sonomoto K
Methods Mol Biol; 2011; 705():225-36. PubMed ID: 21125389
[TBL] [Abstract][Full Text] [Related]
3. Characterization of modification enzyme NukM and engineering of a novel thioether bridge in lantibiotic nukacin ISK-1.
Shioya K; Harada Y; Nagao J; Nakayama J; Sonomoto K
Appl Microbiol Biotechnol; 2010 Apr; 86(3):891-9. PubMed ID: 19915831
[TBL] [Abstract][Full Text] [Related]
4. Lantibiotic engineering: molecular characterization and exploitation of lantibiotic-synthesizing enzymes for peptide engineering.
Nagao J; Aso Y; Shioya K; Nakayama J; Sonomoto K
J Mol Microbiol Biotechnol; 2007; 13(4):235-42. PubMed ID: 17827974
[TBL] [Abstract][Full Text] [Related]
5. Mapping and identification of the region and secondary structure required for the maturation of the nukacin ISK-1 prepeptide.
Nagao J; Morinaga Y; Islam MR; Asaduzzaman SM; Aso Y; Nakayama J; Sonomoto K
Peptides; 2009 Aug; 30(8):1412-20. PubMed ID: 19481127
[TBL] [Abstract][Full Text] [Related]
6. In vitro catalytic activity of N-terminal and C-terminal domains in NukM, the post-translational modification enzyme of nukacin ISK-1.
Shimafuji C; Noguchi M; Nishie M; Nagao J; Shioya K; Zendo T; Nakayama J; Sonomoto K
J Biosci Bioeng; 2015 Dec; 120(6):624-9. PubMed ID: 25971839
[TBL] [Abstract][Full Text] [Related]
7. Engineering dehydro amino acids and thioethers into peptides using lacticin 481 synthetase.
Chatterjee C; Patton GC; Cooper L; Paul M; van der Donk WA
Chem Biol; 2006 Oct; 13(10):1109-17. PubMed ID: 17052615
[TBL] [Abstract][Full Text] [Related]
8. Lantibiotics: insight and foresight for new paradigm.
Nagao J; Asaduzzaman SM; Aso Y; Okuda K; Nakayama J; Sonomoto K
J Biosci Bioeng; 2006 Sep; 102(3):139-49. PubMed ID: 17046525
[TBL] [Abstract][Full Text] [Related]
9. Characterization of new class III lantibiotics--erythreapeptin, avermipeptin and griseopeptin from Saccharopolyspora erythraea, Streptomyces avermitilis and Streptomyces griseus demonstrates stepwise N-terminal leader processing.
Völler GH; Krawczyk JM; Pesic A; Krawczyk B; Nachtigall J; Süssmuth RD
Chembiochem; 2012 May; 13(8):1174-83. PubMed ID: 22556031
[TBL] [Abstract][Full Text] [Related]
10. The biology of lantibiotics from the lacticin 481 group is coming of age.
Dufour A; Hindré T; Haras D; Le Pennec JP
FEMS Microbiol Rev; 2007 Mar; 31(2):134-67. PubMed ID: 17096664
[TBL] [Abstract][Full Text] [Related]
11. A novel lantibiotic, nukacin ISK-1, of Staphylococcus warneri ISK-1: cloning of the structural gene and identification of the structure.
Biosci Biotechnol Biochem; ; . PubMed ID: 11193411
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
